Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
46.7M
-
Number of holders
-
110
-
Total 13F shares, excl. options
-
41.9M
-
Shares change
-
+654K
-
Total reported value, excl. options
-
$534M
-
Value change
-
+$5.22M
-
Put/Call ratio
-
0.97
-
Number of buys
-
61
-
Number of sells
-
-43
-
Price
-
$12.73
Significant Holders of 4D Molecular Therapeutics, Inc. - Common Stock, par value $0.0001 per share (FDMT) as of Q3 2023
125 filings reported holding FDMT - 4D Molecular Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q3 2023.
4D Molecular Therapeutics, Inc. - Common Stock, par value $0.0001 per share (FDMT) has 110 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 41.9M shares
of 46.7M outstanding shares and own 89.77% of the company stock.
Largest 10 shareholders include VIKING GLOBAL INVESTORS LP (4.79M shares), RA CAPITAL MANAGEMENT, L.P. (4.16M shares), BVF INC/IL (4.01M shares), BlackRock Inc. (3.12M shares), VR Adviser, LLC (3M shares), Deep Track Capital, LP (2.78M shares), JANUS HENDERSON GROUP PLC (2.75M shares), VANGUARD GROUP INC (1.9M shares), STATE STREET CORP (1.72M shares), and MORGAN STANLEY (1.47M shares).
This table shows the top 110 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.